Aflibercept (a soluble VEGFR decoy) [140], ZLF-095 (VEGFR 1–3 inhibitor) [141], and BD0801 (anti-VEGF monoclonal antibody) [142] are some of the therapeutics that have shown preclinical activity toward HCC. Here, VEGFA is linked to hepatocellular carcinoma.